Specific and efficient siRNA-mediated ITGB2 or KRAS loss-of-function (LOF) reduced the levels of pEGFR and the downstream target of EGFR signaling VIM, demonstrating the requirement of ITGB2 and KRAS for the activation of EGFR and the RAS/MAPK/ERK signaling in SCLC. The gene discussed is KRAS; the disease is small cell lung carcinoma.